Last update Dec. 7, 2016
Very Low Risk
Prodrug of Mesalazine: Medication compounded by union of two molecules of 5-ASA resulting in a dimer which is degraded into monomeric Mesalazine (5-ASA) in the large intestine.
Mesalazine is badly absorbed by the intestine, serum levels are low with scant excretion into breast milk. Traces of Olsalazine and/or Mesalazine have not been found in breast milk of treated mothers with Olsalazine. N-acetyl-5-ASA is an inactive metabolite which is excreted into breast milk but not higher than 1% of relative infant's dose.
No harm effects among breastfed infants from treated mothers have been reported, except for rare cases of diarrhea reported in the 80's with the use of Mesalazine compounds different to Olsalazine. In a review of 121 cases and 121 controls, the authors failed to observe those findings. (Moretti, 1989).
Expert consensus supports the compatibility of Mesalazine and/or its prodrugs during breastfeeding.
We do not have alternatives for Olsalazine since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.